Abbott Laboratories (ABT) Stock Price, News & Analysis

Company Overview

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability. The medical devices business includes cardiac and vascular products, structural heart therapies, neuromodulation and diabetes-care technologies, notably continuous glucose monitoring systems and insulin-delivery adjuncts. Abbott’s nutrition portfolio features infant formulas, adult nutritional supplements and pediatric nutrition brands designed for clinical and retail settings. The company’s established pharmaceuticals unit develops and markets a range of branded generic medicines in selected international markets.

Abbott has a long corporate history and has reshaped its business through strategic transactions, including a 2013 corporate separation that created AbbVie as an independent research-driven pharmaceutical company and a 2017 acquisition that broadened its medical-device offerings. These moves, together with ongoing investments in research and product development, reflect Abbott’s focus on innovation across diagnostics, devices, nutrition and pharmaceuticals.

Today Abbott serves a global footprint, with products marketed in many countries around the world. The company is led by President and Chief Executive Officer Robert B. Ford and maintains research, manufacturing and distribution operations to support healthcare providers, laboratories, retailers and consumers. Abbott emphasizes collaboration with the medical community and regulatory bodies to advance product availability and patient care worldwide.

Key Stats

• Today's Range: $100.07 to $101.90
• 50-Day Range: $84.49 to $101.72
• 52-Week Range: $81.97 to $137.49
• Volume: 9.95 million shs
• Average Volume: 12.39 million shs
• Market Capitalization: $175.70 billion
• P/E Ratio: 32.64
• Dividend Yield: 2.50%
• Price Target: $118.61
• Consensus Rating: Moderate Buy

Abbott Laboratories Stock Analysis - MarketRank™

Abbott Laboratories scored higher than 97% of companies evaluated by MarketBeat, and ranked 13th out of 835 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 3 strong buy ratings, 19 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Abbott Laboratories has a consensus price target of $118.61, representing about 17.6% upside from its current price of $100.87.

Amount of Analyst Coverage

Abbott Laboratories has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 10.16%

Earnings Growth

Earnings for Abbott Laboratories are expected to grow by 10.16% in the coming year, from $5.51 to $6.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Abbott Laboratories is 32.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of Abbott Laboratories is 32.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.93.

Price to Earnings Growth Ratio

Abbott Laboratories has a PEG Ratio of 1.93. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Abbott Laboratories has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.35% of the float of Abbott Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Abbott Laboratories has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Abbott Laboratories has recently increased by 6.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Abbott Laboratories pays a meaningful dividend of 2.53%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Abbott Laboratories has been increasing its dividend for 54 years.

Dividend Coverage

The dividend payout ratio of Abbott Laboratories is 81.55%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.52% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.92

News Sentiment

Abbott Laboratories has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 81 news articles for Abbott Laboratories this week, compared to 11 articles on an average week.

Search Interest

94 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.

MarketBeat Follows

40 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 208% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Abbott Laboratories in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Abbott Laboratories insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,127,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.46% of the stock of Abbott Laboratories is held by insiders.

Percentage Held by Institutions

75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 5/15 Dividend: 4/15/2026
• Ex-Dividend for 5/15 Dividend: 4/15/2026
• Dividend Payable: 5/15/2026
• Record date for 8/17 Dividend: 7/15/2026
• Ex-Dividend for 8/17 Dividend: 7/15/2026
• Last Earnings: 7/16/2026
• Today: 7/23/2026
• Dividend Payable: 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:ABT
• CIK: 1800
• Web: www.abbott.com
• Phone: (224) 667-6100
• Fax: 847-937-1511
• Employees: 115,000
• Year Founded: 1888

Price Target and Rating

• Average Price Target for Abbott Laboratories: $118.61
• High Price Target: $143.00
• Low Price Target: $92.00
• Potential Upside/Downside: +17.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.96
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.09
• Trailing P/E Ratio: 32.64
• Forward P/E Ratio: 18.31
• P/E Growth: 1.93
• Net Income: $6.52 billion
• Net Margins: 11.65%
• Pretax Margin: 16.12%
• Return on Equity: 17.65%
• Return on Assets: 9.83%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 1.39
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $44.33 billion
• Price / Sales: 3.96
• Cash Flow: $7.07 per share
• Price / Cash Flow: 14.26
• Book Value: $30.35 per share
• Price / Book: 3.32

Miscellaneous

• Outstanding Shares: 1,741,810,000
• Free Float: 1,733,801,000
• Market Cap: $175.70 billion
• Optionable: Optionable
• Beta: 0.61